Form 8-K - Current report:
SEC Accession No. 0001104659-24-071250
Filing Date
2024-06-13
Accepted
2024-06-13 16:05:18
Documents
13
Period of Report
2024-06-11
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2417213d1_8k.htm   iXBRL 8-K 37053
  Complete submission text file 0001104659-24-071250.txt   210674

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ymab-20240611.xsd EX-101.SCH 3006
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ymab-20240611_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ymab-20240611_pre.xml EX-101.PRE 22353
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2417213d1_8k_htm.xml XML 3674
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 241041214
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)